Resubmitted FDA filing advances off-the-shelf EBV-specific T-cell therapy tab-cel for relapsed EBV+ PTLD after transplant, with longer follow-up.
Commentary|Videos|March 16, 2026
Deescalation vs Intensification: How to Ensure Patients Get the Treatment They Need
Author(s)Hua-Jay "Jeff" Cherng, MD
Fact checked by: Paige Britt
MRD testing personalizes diffuse large B‑cell lymphoma therapy—shorten chemo for early responders and flag high‑risk patients for targeted add‑ons.
Advertisement
In an interview with Targeted Oncology, Hua-Jay “Jeff” Cherng, MD, assistant professor of medicine in the lymphoma program in the Division of Hematology and Oncology at the Columbia University Irving Medical Center, discussed how to ensure patients with lymphoma receive the proper level of treatment based on molecular response in clinical trials.
Advertisement
Related to this article
Benjamin Herzberg, MD, discusses KRAS-mutant non–small cell lung cancer, upfront biomarker testing, and the emerging RAS inhibitor toolkit on Targeted Talks.
Published phase 1 findings support the promising efficacy and tolerability of anito-cel in relapsed/refractory multiple myeloma, explains lead author Matthew Frigault, MD.
Broad oncology bundles falter; experts push smaller surgery/radiation episodes, better navigation, and AI analytics to improve value-based care.
In an interview, Peter Voorhees, MD, discusses his presentation of the CERVINO trial data from the International Myeloma Society meeting.
New analysis tracks life-years gained from blood cancer therapies, revealing breakthrough inflection points, stubborn AML gaps, and inequities in access.
For Prostate Cancer Awareness Month, Herbert Lepor, MD, discusses the leading concerns in managing early prostate cancer and tailoring strategies to the patient based on their risk and goals.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Plinabulin Receives FDA Fast Track Designation in Post-ICI NSCLC
2
FDA Oncology Recap: Approvals, Designations, and Decisions in September 2026
3
Denosumab Biosimilar Approved For Existing Oncology Indications
4
CEPHEUS and Frontline Treatment in Newly Diagnosed Multiple Myeloma
5